Quantcast

Latest Biologic Stories

2014-04-29 08:36:38

BEIJING, April 29, 2014 /PRNewwire/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release first quarter 2014 financial results on Tuesday, May 6, 2014 after the market closes. The Company's management will hold a conference call at 8:00 a.m. ET on Wednesday, May 7, 2014, which is 8:00 p.m., Beijing Time on May 7, 2014, to discuss...

2014-04-28 08:31:55

REDWOOD CITY, Calif., April 28, 2014 /PRNewswire/ -- Coherus Biosciences, Inc. ("Coherus"), is pleased to announce the appointment of Michael A. Fleming as Senior Vice President, Commercial Strategy. Mr. Fleming joins Coherus with more than 25 years of experience in strategic and operational leadership roles at preeminent biotech companies. "Michael is a vital addition to the Coherus team at this time," said Denny Lanfear, President and CEO of Coherus. "Our pipeline is now...

2014-04-28 08:31:24

DUBLIN, Apr. 28, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/85rshn/global) has announced the addition of the "Global Therapeutic Vaccines Market 2014-2018" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 A therapeutic vaccine is a biological combination developed to improve immunity by inducing an attack against a diseased cell or tissue. This differs from prophylactic vaccines, which are administered to an individual...

2014-04-23 12:29:37

New Entity YL Biologics to focus on clinical development and commercialization of Biosimilars for Japan MUMBAI and BALTIMORE, April 23, 2014 /PRNewswire/ -- Pharma Major, Lupin Limited (Lupin) announced today that it has entered into a strategic joint venture agreement with Toyama based Japanese pharmaceuticals company, Yoshindo Inc. (Yoshindo) to create a new entity, YL Biologics (YLB). YLB will be jointly managed by both partners and will be responsible for conducting...

2014-04-23 08:31:11

ROCKVILLE, Md., April 23, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today positive preclinical research findings for SYN-005, the Company's proprietary monoclonal antibody (mAb) combination therapy for treating Pertussis (whooping cough), in two non-human primate studies (n=15). In the second pertussis study in...

2014-04-22 12:27:06

Brazilian Public-Private Partnerships Drive Strong Growth in Biosimilars Pipeline, According to Findings from Decision Resources Group BURLINGTON, Mass., April 22, 2014 /PRNewswire/ -- Decision Resources Group finds that the number of publically disclosed biosimilar development projects has increased by more than 40 percent in the last 12 months. The majority of these development projects are yet to enter clinical development, but the 20 percent annual increase in the number of biosimilars in...

2014-04-22 04:21:26

Off-the shelf biologic medical device is now approved and poised for introduction in the EU for use in certain anterior cruciate ligament (ACL) knee surgeries SAN ANTONIO, Texas, April 22, 2014 /PRNewswire/ -- Aperion Biologics, Inc. was granted the CE Mark approval for its lead product, the Z-Lig(TM) ACLR device, to be used by surgeons in the European Union and other territories that accept the CE Mark. The Z-Lig(TM) is the first engineered biologic device for treatment of revision...

2014-04-20 23:01:04

ReportsnReports.com offers Therapeutic Class Overview: Psoriasis – Plaque Psoriasis & Psoriatic Arthritis: Novel Oral drugs and Biologics to Change Future Treatment Paradigm market research report in its store. Dallas, TX (PRWEB) April 20, 2014 Therapeutic Class Overview: Psoriasis – Plaque Psoriasis & Psoriatic Arthritis: Novel Oral drugs and Biologics to Change Future Treatment Paradigm market research report says that over the last decades, therapeutic options for Plaque...

2014-04-16 08:32:44

U.S. Institutional Investors Lead Oversubscribed Round To Advance Monoclonal Antibody Clinical Programs For Companion Animal Health MELBOURNE, Australia, April 16, 2014 /PRNewswire/ -- Nexvet Biopharma, a leading veterinary biologic drug developer, today announced the closing of its US$31.5 million Series B round of financing. Top-tier U.S.-based institutional investors Farallon Capital Management, LLC, Adage Capital Partners, L.P, Foresite Capital, and Tavistock Life Sciences...

2014-04-14 12:33:08

ROCKVILLE, Md., April 14, 2014 Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and other diseases, announced today the formation of a Clinical Advisory Board (CAB) to support development of the Company's constipation-predominant irritable bowel syndrome (C-IBS) program. The Company also announced that pioneering gastroenterologist and lead investigator for the C-IBS...


Word of the Day
ween
  • To think; to imagine; to fancy.
  • To be of opinion; have the notion; think; imagine; suppose.
The word 'ween' comes from Middle English wene, from Old English wēn, wēna ("hope, weening, expectation"), from Proto-Germanic *wēniz, *wēnōn (“hope, expectation”), from Proto-Indo-European *wen- (“to strive, love, want, reach, win”).
Related